Convelo Therapeutics launched publicly on Wednesday, July 25, after working in stealth mode with a mission to discover and develop a new class of medicines for neurological disease characterized by the loss of the protective Myelin coating around nerve cells, according to a news release.
Click here to read full article at Crain's Cleveland Business
